[ Ссылка ]

Without adequate treatments, neurodegenerative diseases such as Alzheimer’s and Parkinson’s remain an important unmet medical burden for aging societies. In a discussion at the 2019 Biotech Showcase, Asceneuron CEO Dirk Beher tells Mike Ward about the progress that the 2012 startup is making with its small-molecule therapeutics that reduce the accumulation of toxic aggregates of the tau protein into the neurofibrillary tangles that are widely recognized as the main cause of neurodegeneration and clinical symptoms in the majority of dementia cases, including Alzheimer’s disease.

свернуть